Mouse LRIG1 Alexa Fluor® 405-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB3688V
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Ala37-Thr794
Accession # P70193
Specificity
Clonality
Host
Isotype
Applications for Mouse LRIG1 Alexa Fluor® 405-conjugated Antibody
Blockade of Receptor-ligand Interaction
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: LRIG1
LRIG1 (formerly LIG-1) is one of three mammalian LRR (leucine-rich repeat) and Ig-like domain-containing type I transmembrane glycoproteins that share 45‑50% amino acid (aa) identity (1, 2). All contain fifteen LRRs flanked by cysteine-rich regions and three C-type Ig-like domains within their extracellular domains (ECD) (1, 2). LRIG1 shows the highest expression in liver, brain, stomach, small intestine and skeletal muscle (2). Expression is prominent in certain epithelia and subsets of glial cells (1, 2). Within the cell, LRIG1 is expressed in the perinuclear region as well as on the surface. Mouse LRIG1 is synthesized with a 37 aa signal sequence, a 759 aa ECD, a 21 aa transmembrane sequence and a 295 aa intracellular region that binds the ubiquitin ligase, c-Cbl (3). LRIG1 binds the EGF receptor (ErbB1) or neuregulin receptors (ErbB2, 3 and 4) via either its LRR or Ig-like domains and promotes ubiquitination, internalization and destruction of these receptors (3, 4). Since LRIG1 modulates growth factor receptor expression, there is an inverse relationship between LRIG1 expression and proliferative capacity. Genetic disruption of mouse LRIG1 results in a psoriasis-like epidermal hyperplasia on the tail and facial area, which is consistent with downregulation of LRIG1 in human psoriatic lesions (5). High ratios of EGF R to LRIG1 in human renal cell carcinomas correlate with poor survival (6). In skin squamous cell carcinomas, high LRIG1 expression correlates with a more differentiated state and a survival benefit (7). Mouse LRIG1 ECD shows 90%, 93%, 90% and 87% aa identity with human, rat, bovine and canine LRIG1 ECD, respectively.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional LRIG1 Products
Product Specific Notices for Mouse LRIG1 Alexa Fluor® 405-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only